BASEL, Switzerland– Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the FDA cleared an IND application for ALE.C04 as a monotherapy and in combination with pembrolizumab, in a first-in-human clinical trial in recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) that is expected to start during the second half of 2023.
“With ALE.C04 we aim to treat solid tumors in a unique way. By targeting exposed CLDN1 on cancer cells our antibody remodels the extracellular matrix favoring T- and NK-cell trafficking, which in turn directly kills CLDN1+ tumor cells and breaks the check-point inhibitor resistance in immune-excluded tumors,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis. “The high unmet medical need, strong scientific rationale and our compelling preclinical and translational data makes HNSCC an ideal first indication for ALE.C04 as a monotherapy and in combination with anti-PD-1 treatment.”
Dr. Roberto Iacone, Chief Executive Officer of Alentis added, “The IND clearance for ALE.C04 is an important step for Alentis as it marks our entry into the oncology space. The planned Phase 1/2 study will tell us a lot about the anti-tumor efficacy of our antibody to treat CLDN1+ tumors. We are the leading company targeting CLDN1 across organ fibrosis and cancer.”
